Robotic repair of traumatic bronchial disruption: A minimally invasive and multi-disciplinary approach to a complex constellation of injuries.

Bronchial disruption is a catastrophic consequence of blunt thoracic trauma with high pre-hospital lethality. This injury is classically managed through a large thoracotomy incision to facilitate adequate exposure for open repair. Here, we describe a case of complete bronchus intermedius disruption following a motor vehicle accident that was repaired via robotic thoracoscopy. The patient sustained multi-system trauma, including a grade III liver laceration, an innominate artery pseudoaneurysm, and femoral condyle fracture, all of which required systematic intervention and multi-disciplinary coordination to best facilitate this patient's care. This patient recovered well from his multiple injuries and was discharged after an uneventful post-operative course.

Tomosynthesis in Breast Cancer Imaging: How Does It Fit into Preoperative Evaluation and Surveillance?

An important limitation of conventional two-dimensional mammography is the overlap of dense breast tissue obscuring masses. Digital breast tomosynthesis (DBT) has emerged as a mammographic technology that overcomes this limitation and is considered an overall better mammogram. DBT has been shown to detect significantly more breast cancer than conventional two-dimensional mammography, and to decrease the number of callbacks for diagnostic evaluation from screening mammography. Usually the callback evaluation is deemed to be overlap of tissue requiring no further management. DBT is used in the screening and diagnostic setting, and for guidance of wire localization or core biopsy, performing more accurately in the dense breast.

A systematic review of clinically available gene expression profiling assays for stage II colorectal cancer: initial steps toward genetic staging.

BACKGROUND: In recent years, increasingly accessible and novel genetic technologies have spurred keen interest in the application of cancer genetics in predicting prognosis and response to treatment. In particular, investigators have eagerly sought to establish and validate genetic signatures that might improve the identification of patients with stage II colorectal cancer (CRC) who are at highest risk of recurrence. To better understand the evidence for incorporation of genetic assays into clinical practice, we have systematically reviewed those assays that have been validated and are available for clinical use in stage II CRC. METHODS: A systematic review was performed using PubMed, Web of Science and Scopus databases. The GRADE system was used to evaluate level of evidence and strength of recommendations. RESULTS: After duplicates were removed and exclusion criteria were applied, there were 13 articles for review. CONCLUSION: Identifying high-risk patients with stage II CRC using molecular profiling has been the primary aim of many investigators, and the approach is translating into clinical utility.